Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2214-2232

  Rich, Tyvin A ^a   Shepard, Robert C ^a   Mosley, Stephen T ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; EMITEFUR; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT;

ANUS CANCER; BILE DUCT CANCER; CHEMOTHERAPY; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; IRRADIATION; PANCREAS CANCER; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; STOMACH CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER; DRUG ADMINISTRATION; DRUG COMBINATION; MULTIMODALITY CANCER THERAPY; NEOPLASM;

ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; NEOPLASMS; PYRIMIDINES; RADIATION-SENSITIZING AGENTS;

EID: 2942648695     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.009     Document Type: Review

References (100)

1. Scrip's Cancer Chemotherapy Report: Scrip World Pharmaceutical News 2002
2. Heidelberger C, Chaudhuari N, Dannenberg P, et al: Fluorinated pyrimidines: A new class of tumor inhibitory compounds. Nature 179:663-666, 1957
3. de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs 19:41-59, 2001
4. Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 7:288-323, 2002
5. Lamont EB, Schilsky RL: The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 5:2289-2296, 1999
6. Sawada N, Ishikawa T, Sekiguchi F, et al: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5:2948-2953, 1999
7. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998
8. Reggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206, 1987
9. Grem JL: Mechanisms of action and modulation of fluorouracil. Semin Radiat Oncol 7:249-259, 1997
10. Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
11. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51, 1988
12. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome. Cancer 68:499-501, 1991
13. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993
14. Lu Z, Zhang R, Carpenter JT, et al: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4:325-329, 1998
15. Sloan JA, Goldberg RM, Sargent DJ, et al: Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491-1498, 2002
16. Kaminski A, Joseph D, Elsaleh H: Toxicity and outcomes in locally advanced rectal cancer treated prospectively with preoperative bolus or infusional 5-fluorouracil chemoradiation. Proc Eur Soc Ther Radiol and Oncol 64:298, 2002 (suppl 1, abstr 462)
17. van Rijnsoever M, Grieu F, Elsaleh H, et al: Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51:797-802, 2002
18. Rich TA: Infusional chemoradiation for operable rectal cancer: Post-, pre-, or nonoperative management? Oncology (Huntingt) 11:295-300, 1997
19. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000
20. Cohen V, Panel-Raymond V, Sabbaghian N, et al: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611-1615, 2003
21. Hughes LL, Luengas J, Rich TA, et al: Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: Effects on cell survival, DNA repair, and cell recovery. Int J Radiat Oncol Biol Phys 23:983-991, 1992
22. Lawrence TS, Tepper JE, Blackstock AW: Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 7:260-266, 1997
23. Rich TA: Irradiation plus 5-fluorouracil: Cellular mechanisms of action and treatment schedules. Semin Radiat Oncol 7:267-273, 1997
24. Thomas PR, Lindblad AS, Stablein DM, et al: Toxicity associated with adjuvant postoperative therapy for adenocarcinoma of the rectum. Cancer 57:1130-1134, 1986
25. Smalley SR, Kimler BF, Evans RG, et al: Heterogeneity of 5-fluorouracil radiosensitivity modulation in cultured mammalian cell lines. Int J Radiat Oncol Biol Phys 24:519-525, 1992
26. Drewinko B, Yang LY: Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep 69:1391-1398, 1985
27. Calabro-Jones PM, Byfield JE, Ward JF, et al: Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 42:4413-4420, 1982
28. Byfield JE, Calabro-Jones P, Klisak I, et al: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 8:1923-1933, 1982
29. Goldman P: Rate-controlled drug delivery. N Engl J Med 307:286-290, 1982
30. Hahn RG, Moertel CG, Schutt AJ, et al: A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. Cancer 35: 1031-1035, 1975
31. Seifert P, Baker LH, Reed ML, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123-128, 1975
32. Meta-analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
33. Meta-analysis Group In Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998
34. NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
35. Hoff PM, Cassidy J, Schmoll H-J: The evolution of fluoropyrimidine therapy: From intravenous to oral. Oncologist 6:3-11, 2001 (suppl 4)
36. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
37. Borner M, Scheithauer W, Twelves C, et al: Answering patients' needs: Oral alternatives to intravenous therapy. Oncologist 6:12-16, 2001 (suppl 4)
38. Borner MM, Schoffski P, de Wit R, et al: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349-358, 2002
39. Mayer RJ: Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: By either route, it's all the same. J Clin Oncol 19:4093-4096, 2001
40. Grem JL: Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. Oncology (Huntingt) 15:13-19, 2001
41. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10:896-903, 1992
42. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
43. O'Dwyer PJ, Manola J, Valone FH, et al: Fluorouracil modulation in colorectal cancer: Lack of improvement with N -phosphonoacetyl- I-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule-An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 19:2413-2421, 2001
44. Lokich J, Ahlgren J: To modulate or not to modulate; to infuse or to bolus; the enigma of 5-fluorouracil is still alive after all these years. J Infus Chemother 6:82-83, 1996
45. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13: 1303-1311, 1995
46. Herskovic A, Leichman L, Lattin P, et al: Chemo/radiation with and without surgery in the thoracic esophagus: The Wayne State experience. Int J Radiat Oncol Biol Phys 15:655-662, 1988
47. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14:2527-2539, 1996
48. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
49. Saif M, Diasio R: Fluoropyrimidines as Radiation Sensitizers, in Choy H (ed): Chemoradiation in Cancer Therapy, 2003
50. Byfield JE: 5-fluorouracil radiation sensitization: A brief review. Invest New Drugs 7:111-116, 1989
51. Byfield JE, Sharp TR, Hornbeck CL, et al: Phase I and pharmacologic study of oral ftorafur and X ray therapy in advanced gastrointestinal cancer. Int J Radiat Oncol Biol Phys 11:597-602, 1985
52. Rich TA, Lokich JJ, Chaffey JT: A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy. J Clin Oncol 3:402-106, 1985
53. Glynne-Jones R, Debus J: Improving chemoradiotherapy in rectal cancer. Oncologist 6:29-34, 2001 (suppl 4)
54. Peters LJ, Ang KK, Thames HD Jr: Accelerated fractionation in the radiation treatment of head and neck cancer: A critical comparison of different strategies. Acta Oncol 27:185-194, 1988
55. Rich TA, Shelton CH III, Kirichenko A, et al: Chronomodulated chemotherapy and irradiation: An idea whose time has come? Chronobiol Int 19:191-205, 2002
56. Rich TA, Kirichenko AV, Sewell R, et al: Modulation of dose intensity in aerodigestive tract cancers: Strategies to reduce toxicity. Oncology (Huntingt) 15:1603-1613, 2001
57. Browman GP, Levine MN, Hodson DI, et al: The Head and Neck Radiotherapy Questionnaire: A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol 11:863-872, 1993
58. Cunningham D, Coleman R: New options for outpatient chemotherapy: The role of oral fluoropyrimidines. Cancer Treat Rev 27:211-220, 2001
59. Norton L: Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 3:30-35, 2001 (suppl 6)
60. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
61. Smalley SR, Benedetti J, Williamson S, et al. M. Intergroup 0144: Phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer-Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc Am Soc Clin Oncol 22, 251, 2003
62. Marra G, Anti M, Percesepe A, et al: Circadian variations of epithelial cell proliferation in human rectal crypts. Gastroenterology 106: 982-987, 1994
63. Buchi KN, Moore JG, Hrushesky WJ, et al: Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 101: 410-415, 1991
64. Smaaland R, Laerum OD, Abrahamsen JF: Circadian cell kinetics in humans: Aspects related to cancer chemotherapy. In Vivo 9:529-537, 1995
65. Bjarnason GA, Jordan RC, Wood PA, et al: Circadian expression of clock genes in human oral mucosa and skin: Association with specific cell-cycle phases. Am J Pathol 158:1793-1801, 2001
66. Cure H, Chevalier V, Adenis A, et al: Phase II trial of chronomodulated infusion of high-dose fluorouracil and I-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 20:1175-1181, 2002
67. Marsh RD, Chu NM, Vauthey JN, et al: Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer 78:217-225, 1996
68. Penberthy DR, Rich TA, Shelton CH III, et al: A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer. Ann Oncol 12:681-684, 2001
69. Levi FA, Zidani R, Vannetzel JM, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 86:1608-1617, 1994
70. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
71. Cure H, Chevalier V, Pezet D, et al: Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer. Anticancer Res 20:4649-4653, 2000
72. Ishikawa T, Utoh M, Sawada N, et al: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097, 1998
73. Ron IG, Lotan A, Inbar MJ, et al: Advanced colorectal carcinoma: Redefining the role of oral ftorafur. Anticancer Drugs 7:649-654, 1996
74. Rustum YM, Cao S, Shirasaka T, et al: A new 5-fluorouracil produrg, S-1, orally bioavailable wth high therapeutic index in model system active in phase II trials. Proc Am Soc Clin Oncol 16:227a, 1997
75. Nakai Y, Furuse K, Ohta M, et al: Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer: A multicenter phase II study. Acta Oncol 33:523-526, 1994
76. Sugimachi K, Maehara Y: A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer. Surg Today 30:1067-1072, 2000
77. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
78. Van Cutsem E, Findlay M, Osterwalder B, et al: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 18:1337-1345, 2000
79. Mayer F, Hartmann JT, von Pawel J, et al: A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors. Ann Oncol 13:755-759, 2002
80. Pazdur R, Royce ME: Novel agents for colorectal cancer. Expert Opin Investig Drugs 8:1639-1652, 1999
81. Hoff PM, Janjan N, Saad ED, et al: Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 18:3529-3534, 2000
82. Schiebe ME, Reese T, Wenz F, et al: Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer. Anticancer Drugs 13: 1005-1009, 2002
83. Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605-3616, 2002
84. Yoshisue K, Hironaga K, Yamaguchi S, et al: Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Pharmacol 46:51-56, 2000
85. Hoff PM, Saad ED, Ajani JA, et al: Phase I study with pharmacokinetics of s-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9:134-142, 2003
86. Fujii S, Fukushima M, Shimamoto Y, et al: Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Res 80: 173-181, 1989
87. Fujii S: [BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents]. Gan To Kagaku Ryoho 14:2244-2250, 1987
88. Schuller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000
89. Kovach JS, Beart RW Jr: Cellular pharmacology of fluorinated pyrimidines in vivo in man. Invest New Drugs 7:13-25, 1989
90. Moghaddam A, Zhang HT, Fan TP, et al: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A 92:998-1002, 1995
91. Kitazono M, Takebayashi Y, Ishitsuka K, et al: Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 253:797-803, 1998
92. Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase. in human colorectal carcinoma. J Natl Cancer Inst 88:1110-1117, 1996
93. Ishitsuka H: Capecitabine: Preclinical pharmacology studies. Invest New Drugs 18: 343-354, 2000
94. Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019, 1998
95. Kurosumi M, Tabei T, Suemasu K, et al: Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7:945-948, 2000
96. Blum JL: The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56-64, 2001
97. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
98. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
99. Moertel CG, Childs DS Jr, Reitemeier RJ, et al: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865-867, 1969
100. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 312:1465-1472, 1985